Evolva and Valent BioSciences to co-develop agricultural bioactives
Advertisement
Evolva and Valent BioSciences Corporation (VBC), a subsidiary of Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.
The collaboration will start by developing yeast strains that make the desired ingredients. Evolva has the primary responsibility for this phase while VBC will be responsible for commercialisation. The companies will work together on scale-up and manufacturing. The first products from the collaboration are expected to be launched in 4-5 years.
Total spending on the project during the next five years is estimated at CHF 12-14 million. Evolva and VBC have agreed to split equally both the R&D costs and profits from active ingredient sales.
Other news from the department career
Most read news
More news from our other portals
Last viewed contents
CONTACT2015: 15th Life Science Job Fair in Heidelberg
Degussa Licenses Genedata's Integrated Bioinformatics Platform to Streamline its Metabolic Engineering Research
Rensselaer Announces $1.59 Million Commitment to Biomolecular Training - NIH Grant Establishes Program to Train Next Generation of Researchers
Growing Alberta's Pool of Biotech Talent via On-line Training
Genentech Again Named the No. 1 Employer in Science Magazine Survey
The European Biotech Crossroads - Back in Lille for 2005
Strong exhibitor line-up for BioFine 2005
ScanBalt Campus - Coordinating Education and Research in ScanBalt BioRegion
A new journal where molecular biology meets clinical research
University of Florida launches unique translational biotechnology master’s program
Freie Universität first institution in Germany to integrate medication management into the pharmacy study program
